Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

A Randomized Controlled Trial Comparing the Efficacy and Safety of IDegLira Versus Basal-Bolus in Patients With Poorly Controlled Type 2 Diabetes and Very High HbA1c ≥9–15%: DUAL HIGH Trial

Diabetes Care(2023)10.2337/dc22-2426Source: DataRank Database

A Randomized Controlled Trial Comparing the Efficacy and Safety of IDegLira Versus Basal-Bolus in Patients With Poorly Controlled Type 2 Diabetes and Very High HbA1c ≥9–15%: DUAL HIGH Trial is a research paper published in Diabetes Care (2023). On theSindex it has a DataRank of 0. It has been cited 17 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access17 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 2.68)OA: greenTopics (28)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (12)

Bobak Moazzami ORCID,Maria Florencia Scioscia ORCID,Cesar Zambrano,Bonnie Albury,Jarrod Saling

Live enrichment

PubMed:37459574 OpenAlex:https://openalex.org/W4384562772

Novo Nordisk

Grant: 1K23DK123384-03

Novo Nordisk

Grant: P30DK111024-04S2

Novo Nordisk

Grant: IIS to Emory University

FWCI

2.68

Citation Percentile

0.9%

Citation Trend

2022

2023

2024

2025

2026

greenLicense: https://www.diabetesjournals.org/journals/pages/license

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10465828/pdf/dc222426.pdf

publisherhttps://diabetesjournals.org/care/article-pdf/46/9/1640/733296/dc222426.pdf

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/10465828

journalhttps://doi.org/10.2337/dc22-2426

Fields of Study

Diabetes Treatment and ManagementDiabetes Management and ResearchDiabetes, Cardiovascular Risks, and Lipoproteins

MeSH Terms

LiraglutideBlood GlucoseDiabetes Mellitus, Type 2Drug CombinationsGlycated HemoglobinHumansHypoglycemiaHypoglycemic AgentsWeight GainInsulin, Long-Acting

Keywords

MedicineLiraglutideType 2 diabetesInsulin degludecHypoglycemiaRandomized controlled trialRegimenUrologyDiabetes mellitusClinical endpointInternal medicineInsulin aspartInsulinEndocrinologyInsulin glargine

Sustainable Development Goals

SDG 0: Good health and well-being